A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
Status:
Withdrawn
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate whether the combination of immune therapy and radiation
therapy to plasmacytoma that can stimulate the immune system to attack and eliminate the
abnormal cells in the bone marrow and perhaps delay or prevent the cancer from worsening.
This study will evaluate whether the immune system responds to the combination of radiation
with immunotherapy. It is possible that that the combination of immune therapy and radiation
may not make any difference in whether or not the patient will develop multiple myeloma in
the future.